Australian Securities and Investments Commission v Wilson

Link copied
Case Copied 23 min read

FEDERAL COURT OF AUSTRALIA

Australian Securities and Investments Commission v Wilson [2020] FCA 873

File number: WAD 259 of 2018
Judge: JACKSON J
Date of judgment: 23 June 2020
Catchwords: PRACTICE AND PROCEDURE - application for witnesses to give evidence by video link - application for counsel to present submissions by video link - witness prevented from entering Australia by reason of SARS-CoV-2 (coronavirus) pandemic - trial unable to proceed without evidence of witness - possible injustice if witness not cross-examined in person - risk of unfair trial - application dismissed
Legislation:

Corporations Act 2001 (Cth) s 180

Evidence Act 1906 (WA) ss 106N, 106R

Federal Court of Australia Act 1976 (Cth) ss 37M, 47A, 47C

Cases cited:

Australian Competition and Consumer Commission v StoresOnline International Inc [2009] FCA 717

Australian Securities and Investments Commission (ASIC) v GetSwift Limited [2020] FCA 504

Campaign Master (UK) Ltd v Forty Two International Pty Ltd (No 3) [2009] FCA 1306; (2009) 181 FCR 152

Capic v Ford Motor Company of Australia Limited (Adjournment) [2020] FCA 486

Corrigan v Commvault Systems (Aust) Pty Ltd [2011] FCA 107; (2011) 192 FCR 71

Director of the Fair Work Building Industry Inspectorate v Construction, Forestry, Mining and Energy Union [2015] FCA 627; (2015) 231 FCR 531

Haiye Developments Pty Ltd v The Commercial Business Centre Pty Ltd [2020] NSWSC 732

JKC Australia LNG Pty Ltd v CH2M Hill Companies Ltd [2020] WASCA 38

Re HIH Insurance (in prov liq); Australian Securities and Investments Commission v Adler [2002] NSWSC 483; (2002) 42 ACSR 80

Roberts-Smith v Fairfax Media Publications Pty Limited (No 4) [2020] FCA 614

Date of hearing: 19 June 2020
Registry: Western Australia
Division: General Division
National Practice Area: Commercial and Corporations
Sub-area: Corporations and Corporate Insolvency
Category: Catchwords
Number of paragraphs: 41
Counsel for the Plaintiff: Mr S Vandongen SC with Mr S Wong
Solicitor for the Plaintiff: Australian Securities & Investments Commission
Counsel for the Defendant: Mr GR Donaldson SC with Mr T Russell
Solicitor for the Defendant: Mizen + Mizen

ORDERS

WAD 259 of 2018
BETWEEN:

AUSTRALIAN SECURITIES AND INVESTMENTS COMMISSION

Plaintiff

AND:

FRANK CULLITY WILSON

Defendant

JUDGE:

JACKSON J

DATE OF ORDER:

23 JUNE 2020

THE COURT ORDERS THAT:

1.The plaintiff's interlocutory application dated 3 June 2020 is dismissed with liberty to apply.

2.The case management hearing is adjourned to 2 September 2020 at 9.30 am WST.

3.The costs of the application and of the case management hearing on 19 June 2020 are costs in the cause.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

JACKSON J:

  1. This is an interlocutory application for orders permitting testimony and the appearances and submissions of counsel at trial to proceed by way of video link.  The application has been prompted by the current SARS-CoV-2 (coronavirus) pandemic.

  2. In the proceeding the plaintiff, the Australian Securities and Investments Commission (ASIC), seeks declarations that the defendant, Mr Wilson, contravened s…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Australian Securities and Investments Commission v Wilson and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2020] FCA 873
Decision Date

CaseChat Overview and Summary

This case involves an application by the Australian Securities and Investments Commission (ASIC) to the Federal Court to allow witnesses to give evidence and counsel to present submissions via video link due to the COVID-19 pandemic. The primary respondent, Mr Wilson, contests this application, asserting that it may result in an unfair trial if the evidence is not presented in person, particularly regarding the credibility of a key witness, Dr Castella. The court was required to decide whether the discretion to allow video links should be exercised in favour of adducing the evidence of the United States and Melbourne-based witnesses via video link, given the international travel restrictions and the importance of Dr Castella's evidence to the outcome of the case.

The court considered several factors in exercising its discretion, including the importance of Dr Castella's evidence to the case, the risk that Mr Wilson would not have a fair opportunity to test the evidence of Dr Castella if it was not given in person, and the need to balance the overriding purpose of facilitating the just resolution of disputes quickly, inexpensively, and efficiently. The court noted that the choice in every case cannot be determined solely by reference to general principles but by applying those principles to the facts and circumstances of the particular case. It found that there was a real risk that Mr Wilson would not have a fair and proper opportunity to test the evidence of Dr Castella if it was not given in person, and that the outcome on a critical issue relies to a significant extent on Dr Castella's evidence. However, the court ultimately dismissed the application, finding that the overriding purpose of facilitating the just resolution of disputes quickly, inexpensively, and efficiently outweighed the need for in-person evidence in this case.

The court's reasoning was based on the fact that the evidence of relevant written communications between Mr Wilson and Dr Castella during the key period is limited, and the nature of Dr Castella's evidence in this particular case is largely contained in two affidavits that ASIC has filed. The court found that the risk of unfair trial did not outweigh the need to balance the overriding purpose of facilitating the just resolution of disputes quickly, inexpensively, and efficiently. The court also noted that the application was dismissed with liberty to apply, meaning that ASIC could reapply if circumstances change. The case management hearing was adjourned to 2 September 2020 at 9.30 am WST, and the costs of the application and of the case management hearing on 19 June 2020 were costs in the cause.

Orders

Orders of the court

1. The plaintiff's interlocutory application dated 3 June 2020 is dismissed with liberty to apply.

2. The case management hearing is adjourned to 2 September 2020 at 9.30 am WST.

3. The costs of the application and of the case management hearing on 19 June 2020 are costs in the cause.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

The other matter which the Federal Court Act expressly makes relevant is that under s 37M(4), powers conferred by civil practice and procedure provisions of the Act must be exercised in the way that best promotes the overarching purpose of those provisions as described in s 37M(1), to facilitate the just resolution of disputes according to law and as quickly, inexpensively and efficiently as possible.Relevant issues and evidence in the proceeding The question in this application is whether, informed by those matters, the discretion should be exercised in favour of adducing the evidence of, at least, the United States and Melbourne based witnesses by video link. I have said it arises most acutely in relation to Dr Castella; that is both because of the existence of international travel restrictions and because, as it happens, his evidence is likely to be important to the outcome of the case. In order to appreciate why that is so, it is necessary to describe ASIC's allegations against Mr Wilson in overview. The claim principally concerns events between September 2016 and March 2017. During that period, Mr Wilson was managing director of Quintis. Quintis was listed on the Australian Securities Exchange (ASX) and was subject to continuous disclosure obligations under the Corporations Act and the ASX Listing Rules. Quintis's business involved sandalwood plantations, including the supply of pharmaceutical-grade East Indian sandalwood oil. Two United States subsidiaries of Quintis, Santalis Pharmaceuticals Inc and Santalis Healthcare Corporation, had previously entered into licence and supply agreements with Galderma SA, a subsidiary of Nestlé, which provided for the sale of a substantial volume of sandalwood oil to Galderma over a period of 20 years. ASIC alleges that in November 2016, Galderma told Santalis Pharmaceuticals Inc that it wanted to terminate the supply agreements. It claims that Mr Wilson knew about this from December 2016, but did not tell the other members of Quintis's board of directors. ASIC alleges that on 16 December 2016, Galderma entered into agreements with the two Santalis subsidiaries terminating the supply agreements. Once again, it is said that Mr Wilson knew about this but did not tell Quintis's board. It is alleged that the board did not find out about the termination until May 2017. A market announcement was made soon after that and, in June 2017, a write‑off linked to the cancellation of the Galderma supply agreements was made in Quintis's financial statements. ASIC claims that by withholding knowledge of the termination from the board, Mr Wilson exposed Quintis to legal proceedings for breach of its continuous disclosure obligations, and representative proceedings against it have been commenced. It also claims that on 27 March 2017, in response to a query from the ASX, Mr Wilson authorised and approved a market announcement about the Galderma supply agreements that was misleading and deceptive. All of these things are said to have involved breaches by Mr Wilson of statutory duties as a director of Quintis.

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established

While these cases provide guidance on the approach the court must take, the reason to exercise the discretion 'is to be found in any individual proceeding in the facts and circumstances of each proceeding and by reference to the overriding consideration of ensuring that justice is done as between the parties to that proceeding': Corrigan at [12]. So, as Edmonds J said in Australian Competition and Consumer Commission v StoresOnline International Inc [2009] FCA 717 at [14]:… the choice in every case cannot be determined solely by reference to general principles because it is the application of those principles to the facts and circumstances of the particular case which must determine the choice; in the circumstances of a particular case, a matter may point one way and in another case it may point another way. At the end of the day, the exercise of the discretion as to what is appropriate in a particular case will involve a balancing exercise as to what will best serve the administration of justice consistently with maintaining justice between the parties …Consideration There are several matters relevant to the exercise of the discretion here, including two particular circumstances in the present case which weigh most heavily in that exercise. They are on opposite sides of the balance. The first matter of particular significance is that, in my view, there is a real risk that Mr Wilson will not have a fair and proper opportunity to test the evidence of Dr Castella if that evidence is not given in person. This is a proceeding in which allegations are made of serious misconduct on Mr Wilson's part, which if made out could result in orders for a pecuniary penalty and disqualification against him. Both parties accept, at the least, that the outcome on a critical issue relies to a significant extent on Dr Castella's evidence. It is likely that when Mr Wilson learned of the proposed termination of the Galderma supply agreements, and when and how much he knew about the actual termination, will be central. It is common ground that the credibility of Dr Castella's evidence about that is likely to be in issue. It does not necessarily follow from those matters alone that cross‑examination by video link would be unsatisfactory. But it is also necessary to consider the nature of Dr Castella's evidence in this particular case. It is contained in two affidavits that ASIC has filed. Its tenor is that Dr Castella had several conversations with Mr Wilson during the period November 2016 to February 2017 about the termination of the Galderma supply agreements. Importantly, those conversations did not result in or coincide with any written record of Dr Castella's communications with Mr Wilson on the subject during the relevant time. The evidence of relevant written communications between the two men in the key period is confined to one unclear reference in an email to what, according to Dr Castella, is the subject of the termination of the Galderma agreements. There are also some text messages and further emails that may be relevant, but they date from April to June 2017, after Mr Wilson resigned as a director of Quintis.